New Funding Opportunities from the National Institutes for Neurological Disorders & Stroke (NINDS)
Thursday, September 4 2014
8:00 am – 10:00 am
Location: MassBio, 300 Technology Square, 8th Floor, Cambridge, MA
The Office of Translational Research (OTR) at the National Institutes for Neurological Disorders and Stroke (NINDS) has launched a new suite of non-dilutive funding programs to support academic investigators and small businesses to engage in therapeutic and device discovery and development in neurological disorders. This support begins with assay development through to initial test of clinical candidate in human trials.
OTR has embarked on a sustained campaign to build public-private partnerships to ensure that projects funded by OTR are being appropriately de-risked to support downstream investment from other stakeholders, such as pharma, biotech, venture capital, and patient organizations.
The emerging priorities of the OTR are to ensure that therapeutic development is partnered with the development of mechanistic biomarkers to provide a deeper understanding of the mechanism of action of the therapeutic candidate.
- Rajesh Ranganathan, PhD, Director, Office of Translational Research, NINDS
- Masha Fridkis-Hareli MSc, PhD, Founder and President, ATR, LLC
Our esteemed speaker will describe:
- NINDS’s funding mechanisms
- Results of this campaign to date and
- How funded entities as well as potential funders might be able to benefit.
Come join us for this fascinating presentation and bring your questions.
This event is presented by the Drug Discovery Forum Working Group.
Masha Fridkis-Hareli MSc, PhD, Founder and President, ATR, LLC
Masha Fridkis-Hareli is an immunologist, consultant and inventor with over 20 years of experience in academia and industry. She holds a B.A. from the Technion, an M.Sc. from Hebrew University and a Ph.D. from the Weizmann Institute of Science in Israel. During her post-doctoral training at the Harvard University she designed and developed a group of novel compounds for treatment of autoimmune diseases currently in Phase II clinical trials. After serving as Principal Investigator at the Molecular Immunology Foundation at the Dana Farber Cancer Institute, she transitioned to industry where she held a variety of positions with increasing responsibilities at a number of biotechnology companies and contract research organizations including Resolvyx Pharmaceuticals, Charles River Laboratories, Taligen Therapeutics and Alexion Pharmaceuticals. Dr. Fridkis-Hareli is a co-author of over 100 publications and 13 issued patents. She is an Adjunct Professor at the Graduate Biopharmaceutical Leadership Program at Emmanuel College teaching a course on research in a global environment. Dr. Hareli is a Founder and President of ATR, LLC that provides strategic and operational services in translational research. In addition to her professional affiliations, Dr. Fridkis-Hareli is actively involved on boards of several women’s professional organizations and has recently served as President of the Association for Women in Science in Massachusetts.
Rajesh Ranganathan, PhD, Director, Office of Translational Research (OTR) at National Institutes for Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH)
Dr. Rajesh Ranganathan has been in this role since Jan. 2012. The OTR currently has five funding programs that aim to provide a breadth of opportunities for academic investigators and small businesses to engage in the spectrum of work, beginning with assay development through to initial test of clinical candidate in human trials. The emerging priorities of the office are to ensure that therapeutic development is partnered with the development of mechanistic biomarkers to facilitate deeper understanding of the mechanism of action of the therapeutic candidate. Additionally, there will be emphasis going forward on engaging other stakeholders, such as pharma, biotech, venture capital, and patient organizations to ensure that projects in the office's portfolio have been appropriately de-risked to ensure downstream investments, which will accelerate getting the much-needed therapies to patients suffering from neurological disorders.
Previously, Dr. Ranganathan served in the NIH Office of the Director beginning in Nov. 2010 as the Senior Advisor to the NIH Director for Translational Medicine. Prior to that, spent 7+ years at the Novartis Institutes for BioMedical Research Inc. where he was a Director in the scientific strategy and portfolio management group and also founded and led a Global Office of Scientific Education for the Institutes. Dr. Ranganathan received his Bachelor’s Degrees in Biology and Chemistry from Amherst College, performed his doctoral training with Dr. H. Robert Horvitz at MIT in C. elegans neurobiology, and his postdoctoral training with Dr. Linda Buck at Harvard Medical School and the Fred Hutchinson Cancer Research Center in the area of mammalian sensory regulation.
This Forum is presented by the Drug Discovery Forum Working Group.